Tafuramycin-A

Tafuramycin-A (TFA) is a small molecule chemical compound belonging to the seco-cyclopropyl pyrrolo indole (CPI) analogue class, developed at Griffith University in Queensland, Australia. It functions as a potent DNA-alkylating agent that irreversibly binds to DNA, thereby preventing cellular replication. While it possesses anticancer properties, its primary clinical application is as a chemical attenuation agent in the development of whole-parasite malaria vaccines. In this context, TFA is used to treat *Plasmodium falciparum* (e.g., strain 7G8) infected red blood cells, rendering the parasites non-replicating while preserving their structural integrity and immunogenicity. This approach allows for the creation of a chemically attenuated blood-stage malaria vaccine. Clinical Phase 1 studies have demonstrated that TFA-attenuated parasites are safe, well-tolerated, and capable of inducing a long-lasting CD4+ T cell-dependent immune response in malaria-naive volunteers.